"Sulfonylurea Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Descriptor ID |
D013453
|
MeSH Number(s) |
D02.886.590.795 D02.948.828
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Sulfonylurea Compounds".
Below are MeSH descriptors whose meaning is more specific than "Sulfonylurea Compounds".
This graph shows the total number of publications written about "Sulfonylurea Compounds" by people in this website by year, and whether "Sulfonylurea Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2003 | 0 | 1 | 1 |
2004 | 1 | 0 | 1 |
2009 | 1 | 0 | 1 |
2010 | 0 | 1 | 1 |
2013 | 1 | 0 | 1 |
2014 | 1 | 0 | 1 |
2015 | 2 | 1 | 3 |
2016 | 1 | 0 | 1 |
2017 | 1 | 0 | 1 |
2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sulfonylurea Compounds" by people in Profiles.
-
Heyward J, Mansour O, Olson L, Singh S, Alexander GC. Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. PLoS One. 2020; 15(6):e0234065.
-
Nunes AP, Iglay K, Radican L, Engel SS, Yang J, Doherty MC, Dore DD. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. Diabetes Obes Metab. 2017 10; 19(10):1425-1435.
-
Tate MD, Ong JDH, Dowling JK, McAuley JL, Robertson AB, Latz E, Drummond GR, Cooper MA, Hertzog PJ, Mansell A. Reassessing the role of the NLRP3 inflammasome during pathogenic influenza A virus infection via temporal inhibition. Sci Rep. 2016 06 10; 6:27912.
-
Lapane KL, Jesdale BM, Dub? CE, Pimentel CB, Rajpathak SN. Sulfonylureas and risk of falls and fractures among nursing home residents with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2015 Aug; 109(2):411-9.
-
Chang HY, Hsieh CF, Singh S, Tang W, Chiang YT, Huang WF. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan. Pharmacoepidemiol Drug Saf. 2015 Jun; 24(6):567-75.
-
Rajpathak SN, Fu C, Brodovicz KG, Engel SS, Lapane K. Sulfonylurea use and risk of hip fractures among elderly men and women with type 2 diabetes. Drugs Aging. 2015 Apr; 32(4):321-7.
-
Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Sheng Duh M, Lefebvre P. Quality measure attainment in patients with type 2 diabetes mellitus. Am J Manag Care. 2014 Jan; 20(1 Suppl):s5-15.
-
Lapane KL, Yang S, Brown MJ, Jawahar R, Pagliasotti C, Rajpathak S. Sulfonylureas and risk of falls and fractures: a systematic review. Drugs Aging. 2013 Jul; 30(7):527-47.
-
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, Pollak M, Regensteiner JG, Yee D. Diabetes and cancer: a consensus report. CA Cancer J Clin. 2010 Jul-Aug; 60(4):207-21.
-
Marchand P, Antoine M, Le Baut G, Czech M, Baasner S, G?nther E. Synthesis and structure-activity relationships of N-aryl(indol-3-yl)glyoxamides as antitumor agents. Bioorg Med Chem. 2009 Sep 15; 17(18):6715-27.